| Pegasys (pegylated interferon α -2a) / Roche |
NCT00048945: Efficacy and Safety Study of Pegasys in the Treatment of Chronic Hepatitis B |
|
|
| Completed | 3 | 820 | US, Canada, Europe, RoW | PEGASYS | Hoffmann-La Roche | Chronic Hepatitis B | 10/04 | 10/04 | | |
NCT00221286: Efficacy and Safety of PegIFN +/- FTC / TDF to Treat Chronic Hepatitis B in HIV-Coinfected Patients |
|
|
| Terminated | 3 | 2 | Europe | pegylated interferon alfa-2a, tenofovir DF / emtricitabine combination therapy, pegIFN / TDF / FTC combination therapy | University Hospital, Bonn, Hoffmann-La Roche | Chronic Hepatitis B, HIV Infections | 01/07 | 01/07 | | |
NCT00412750: Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) |
|
|
| Terminated | 3 | 159 | US | Telbivudine (LdT), Sebivo, peginterferon alpha-2a, Pegasys | Novartis | Hepatitis B | 02/09 | 02/09 | | |
NCT01237496 / 2005-000336-25: Analysis of HBV-Specific Immune Response in Patients With HBeAg Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a (40KD)) - Immunology Sub-Study of ML18253 |
|
|
| Completed | 3 | 17 | Europe | peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 09/09 | 09/09 | | |
NCT01095835 / 2004-002985-39: A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV) |
|
|
| Completed | 3 | 131 | Europe | Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg, Pegasys®, Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg, Lamivudine (LAM) | Hoffmann-La Roche | Hepatitis B, Chronic | 01/10 | 01/10 | | |
ADVANCE, NCT00661076: Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B |
|
|
| Completed | 3 | 10 | RoW | adefovir dipivoxil, peginterferon alfa-2a [Pegasys] | Hoffmann-La Roche | Hepatitis B, Chronic | 05/11 | 05/11 | | |
NCT01892241: Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA |
|
|
| Completed | 3 | 74 | RoW | Pegasys(Roche), peginterferon alfa-2a, Entecavir | Third Affiliated Hospital, Sun Yat-Sen University | Antiviral Treatment of Chronic Hepatitis B | 11/12 | 02/13 | | |
NCT01697501 / 2012-002777-56: A Study Evaluating IL28B Polymorphism in Patients With HBeAg-Negative Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML18253 |
|
|
| Completed | 3 | 88 | Europe | Interleukin 28B testing | Hoffmann-La Roche | Hepatitis B, Chronic | 06/13 | 06/13 | | |
NCT01760122: Efficacy and Safety of Peginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B |
|
|
| Completed | 3 | 820 | RoW | Ypeginterferon alfa-2b, Pegasys | Xiamen Amoytop Biotech Co., Ltd., Peking University First Hospital | Chronic Hepatitis B | 07/15 | 08/15 | | |
MK-4031-376, NCT01641926: A Study of the Safety and Efficacy of Pegylated Inferferon Alfa-2b (PEG-Intron™) Versus Pegylated Interferon Alfa-2a (PEGASYS™) in Participants With Chronic Hepatitis B (P08450) |
|
|
| Terminated | 3 | 402 | NA | PEG-Intron™, SCH 054031, Pegylated interferon alfa-2b, PEGASYS™, Pegylated interferon alfa-2a | Merck Sharp & Dohme LLC | Hepatitis B, Chronic | 01/16 | 01/16 | | |
HB01EMVIPEG, NCT00391638: Efficacy and Tolerance of Peg-interferon Alpha 2a Added to Tenofovir and Emtricitabine in AgHBe Positive HBV-HIV Co-infected Patients |
|
|
| Completed | 2/3 | 56 | Europe | TRUVADA (EMTRICITABINE + TENOFOVIR DF), PEGASYS 180μg (Interféron pégylé alpha -2a) | French National Agency for Research on AIDS and Viral Hepatitis, Gilead Sciences, Roche Pharma AG | Hepatitis B, HIV Infections | 05/11 | 10/12 | | |
